from SAT 7:00 PM EST until SUN 1:00 PM EST, Meriwether County, Troup County, Haralson County, Morgan County, Walker County, Putnam County, Spalding County, Pike County, Jasper County, Hall County, ...

Add Yahoo as a preferred source to see more of our stories on Google. If you feel pain and pressure in your sinuses, that's not necessarily because there's anything wrong with them. In fact, your pain ...

The US Food and Drug Administration (FDA) has approved zolmitriptan nasal spray (Zomig, Impax Specialty Pharma) for the acute treatment of migraine with or without aura in children 12 years of age and ...

NEW YORK (Reuters Health) - A nasal spray containing the drug zolmitriptan, which is known by the brand name Zomig, effectively relieves migraine headache in adolescents and is well tolerated, ...

SAN DIEGO — A single dose of a dihydroergotamine mesylate (DHE) nasal powder formulation appears to quickly and significantly reduce migraine pain, results of a new phase 3 study showed. DHE is an ...

The recommended dose of Atzumi is 5.2mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for ...

The FDA approved dihydroergotamine (DHE) nasal powder (Atzumi) 5.2 mg to treat acute migraine with or without aura in adults, Satsuma Pharmaceuticals announced Wednesday. The product is the only DHE ...

KANSAS CITY, Mo. (KCTV) - This rainy weather plus the incoming holiday stress can trigger migraines. But there’s a brand new medicine available for that. It’s called Timolol nasal spray and was ...

Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...

Please provide your email address to receive an email when new articles are posted on . Affecting more than 1 billion people worldwide, migraine is among the most common neurological diseases. During ...

The Food and Drug Administration has granted OptiNose Inc. approval to initiate phase-III testing of an acute migraine headache treatment. The drug uses the company’s bi-direction intranasal ...